Allogene Therapeutics
Bharat Devapatla is a highly experienced scientist with a focus on analytical development and quality control in the biotechnology field. Currently serving as Principal Scientist of Analytical Development at Allogene Therapeutics since March 2021, Bharat has previously held positions as Senior Scientist and Scientist in Quality Control at Cytovance Biologics from November 2016 to February 2021. Earlier in the career, Bharat was a Postdoctoral Researcher at the University of Oklahoma Health Sciences Center from 2013 to 2016 and a Postdoctoral Associate at the University of Louisville from April 2009 to December 2012. Bharat obtained a Ph.D. in Animal Sciences from the University of Hyderabad between 2003 and 2008.
This person is not in the org chart
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.